HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A massive block deal unfolded in the pharmaceutical sector as major institutional players shook up the equity structure of Corona Remedies Limited. High-profile investors, including HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA), stepped in to acquire significant stakes during this high-value transaction.
Details of the Massive Divestment
On June 17, 2026, a significant portion of the equity in Corona Remedies was offloaded through a coordinated block deal on the stock exchange. The primary seller, Sepia Investments, divested 43,28,943 shares at a price of ₹1,730 per share, amounting to approximately ₹748.9 crore.
Adding to the selling pressure, Anchor Partners also participated in the divestment, offloading 1,61,861 shares at the same price of ₹1,730 per share, worth roughly ₹28 crore. When combined, these two entities successfully exited positions worth a total of approximately ₹776.9 crore in the pharmaceutical company.
Institutional Heavyweights Drive the Buy Side
The transaction saw aggressive participation from twelve different institutional investors, signaling strong confidence in Corona Remedies' long-term prospects. HDFC Mutual Fund emerged as the dominant force on the buy side, acquiring 24,50,000 shares. This purchase, valued at roughly ₹423.9 crore, accounted for more than half of the total deal value.
Other prominent domestic and international players included:
- Aditya Birla Sun Life Mutual Fund: Purchased 4,90,000 shares worth ₹84.8 crore.
- Aberdeen Asian Smaller Companies Investment Trust Plc: Acquired 4,50,868 shares for approximately ₹78 crore.
- Invesco Mutual Fund: Picked up 2,89,017 shares worth about ₹50 crore.
- Kotak Mahindra Mutual Fund: Bought 1,61,861 shares, mirroring the exact quantity sold by Anchor Partners, in a deal worth ₹28 crore.
Global and Specialized Funds Join the Fold
The deal attracted significant interest from global sovereign wealth funds and emerging market specialists. The Abu Dhabi Investment Authority (ADIA) entered the fray by purchasing 39,130 shares valued at ₹6.8 crore.
WhiteOak ecosystem ਅਤੇ Aberdeen ਫੰਡਾਂ ਨੇ ਵੀ ਭਾਰੀ ਦਿਲਚਸਪੀ ਦਿਖਾਈ। Aberdeen Standard Sicav I - Asian Smaller Companies Fund ਨੇ ਲਗਭਗ ₹47.4 ਕਰੋੜ ਦਾ ਨਿਵੇਸ਼ ਕੀਤਾ, ਜਦੋਂ ਕਿ WhiteOak Capital Mutual Fund ਅਤੇ Ashoka WhiteOak Emerging Markets Equity Fund ਨੇ ਕ੍ਰਮਵਾਰ ₹25.1 ਕਰੋੜ ਅਤੇ ₹25.7 ਕਰੋੜ ਦੇ ਹਿੱਸੇ ਖਰੀਦੇ। Factory Mutual Insurance Company ਅਤੇ TCW White Oak Emerging Markets Equity Fund ਦੁਆਰਾ ਛੋਟੇ ਪੱਧਰ 'ਤੇ ਨਿਵੇਸ਼ ਕੀਤੇ ਗਏ, ਜੋ ਕਿ ਬਹੁਤ ਹੀ ਉੱਨਤ ਪੂੰਜੀ ਪ੍ਰਦਾਤਾਵਾਂ ਦੇ ਇੱਕ ਵਿਭਿੰਨ ਸਮੂਹ ਨੂੰ ਪੂਰਾ ਕਰਦੇ ਹਨ।
ਮੁੱਖ ਨਿਚੋੜ
- ਮੁੱਖ ਨਿਕਾਸ: Sepia Investments ਅਤੇ Anchor Partners ਨੇ ਮਿਲ ਕੇ Corona Remedies ਵਿੱਚ ਲਗਭਗ ₹776.9 ਕਰੋੜ ਦੇ ਸ਼ੇਅਰ ਵੇਚ ਦਿੱਤੇ।
- HDFC MF ਦਾ ਦਬਦਬਾ: HDFC Mutual Fund ਸਭ ਤੋਂ ਵੱਡਾ ਖਰੀਦਦਾਰ ਸੀ, ਜਿਸ ਨੇ ₹423.9 ਕਰੋੜ ਦੇ ਨਿਵੇਸ਼ ਨਾਲ ਕੁੱਲ ਡੀਲ ਦੀ ਕੀਮਤ ਦਾ 50% ਤੋਂ ਵੱਧ ਹਿੱਸਾ ਖਰੀਦਿਆ।
- ਸੰਸਥਾਗਤ ਵਿਸ਼ਵਾਸ: ADIA ਵਰਗੇ ਵਿਸ਼ਵਵਿਆਪੀ ਦਿੱਗਜਾਂ ਅਤੇ ਵੱਖ-ਵੱਖ Aberdeen ਅਤੇ WhiteOak ਫੰਡਾਂ ਦੀ ਭਾਗੀਦਾਰੀ ₹1,730 ਦੇ ਮੁੱਲ 'ਤੇ ਕੰਪਨੀ ਵਿੱਚ ਮਜ਼ਬੂਤ ਸੰਸਥਾਗਤ ਦਿਲਚਸਪੀ ਨੂੰ ਦਰਸਾਉਂਦੀ ਹੈ।